Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunityBio, Inc.IBRX · Entity 3618 | Director · CEO & President | February 22, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunityBio, Inc.
Report date February 22, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 637,904 |
Reported balance
After 2026-02-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-22 · Exercise / conversion · Acquired 152,439 · Balance 637,904 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. |
| Common StockSEC Table I · non-derivative | Direct | 560,344 |
Reported balance
After 2026-02-22 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-22 · Tax withholding · Disposed 77,560 · Balance 560,344 F2: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 152,439 |
Reported balance
After 2026-02-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-22 · Exercise / conversion · Disposed 152,439 · Balance 152,439 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
F2: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2026 Filed Feb 25, 2026 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 152,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,439 Underlying: Common Stock · 152,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 77,560 | $8.70 | $674,772.00 |
DisclosureSEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,344 F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 152,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 637,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 274,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 548,246 Underlying: Common Stock · 274,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 140,048 | $6.93 | $970,532.64 |
DisclosureSEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,465 F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:50 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 274,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:10 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,731 Underlying: Common Stock · 34,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:10 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 17,510 | $1.98 | $34,669.80 |
DisclosureSEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,391 F2 · price: On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:10 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 152,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000021 · wk-form4_1740535870.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,878 Underlying: Common Stock · 152,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 78,167 | $3.42 | $267,331.14 |
DisclosureSEC source: 0001326110-25-000021 · wk-form4_1740535870.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,418 F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 02:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 152,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000021 · wk-form4_1740535870.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 01:16 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 2,812,500 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001326110-25-000011 · wk-form4_1739409389.xml · derivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,812,500 Underlying: Common Stock · 2,812,500 shares Expires 2035-02-10 F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 10, 2025. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 01:16 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 822,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000011 · wk-form4_1739409389.xml · derivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,368 Underlying: Common Stock · 822,368 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:54 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000004 · wk-form4_1735941268.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,214 Underlying: Common Stock · 34,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F2 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:54 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 17,475 | $2.56 | $44,736.00 |
DisclosureSEC source: 0001326110-25-000004 · wk-form4_1735941268.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,146 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:54 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-25-000004 · wk-form4_1735941268.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:38 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 1,591,463 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001326110-24-000025 · wk-form4_1708983489.xml · derivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,591,463 Underlying: Common Stock · 1,591,463 shares Expires 2034-02-22 F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:38 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantRestricted Stock Units · Derivative | 457,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000025 · wk-form4_1708983489.xml · derivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457,317 Underlying: Common Stock · 457,317 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 02:14 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 83,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000018 · wk-form4_1707272064.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award vested in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares vested on the third anniversary of the vesting commencement date, such that all shares were vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award was February 5, 2021. F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award vested in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares vested on the third anniversary of the vesting commencement date, such that all shares were vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award was February 5, 2021. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 02:14 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 43,165 | $4.04 | $174,386.60 |
DisclosureSEC source: 0001326110-24-000018 · wk-form4_1707272064.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,138 Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 02:14 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 83,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000018 · wk-form4_1707272064.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 02:40 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,697 Underlying: Common Stock · 34,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 02:40 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 17,096 | $5.02 | $85,821.92 |
DisclosureSEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,969 F1 · price: On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 02:40 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 34,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-24-000007 · wk-form4_1704336033.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2023 Filed Feb 7, 2023 23:23 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000010 · wf-form4_167581216683429.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. Read SEC document |
| February 05, 2023 Filed Feb 7, 2023 23:23 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 42,192 | $4.33 | $182,691.36 |
DisclosureSEC source: 0001326110-23-000010 · wf-form4_167581216683429.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,582 F2 · price: On February 5, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 3, 2022 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 05, 2023 Filed Feb 7, 2023 23:23 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000010 · wf-form4_167581216683429.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| December 31, 2022 Filed Jan 5, 2023 02:48 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000004 · wf-form4_167288691221514.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,180 Underlying: Common Stock · 8,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| December 31, 2022 Filed Jan 5, 2023 02:48 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 4,273 | $5.07 | $21,664.11 |
DisclosureSEC source: 0001326110-23-000004 · wf-form4_167288691221514.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,441 F1 · price: On December 31, 2022, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2022 was the settlement price used to calculate the shares withheld. Read SEC document |
| December 31, 2022 Filed Jan 5, 2023 02:48 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-23-000004 · wf-form4_167288691221514.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2022 Filed Mar 26, 2022 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0001326110-22-000018 · wf-form4_164825664654486.xml · derivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-03-23 F2 · derivative.exercise_date: Subject to the Issuer's attainment of a financial goal for fiscal year 2022, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date. The vesting commencement date for this option is March 23, 2022. Read SEC document |
| March 23, 2022 Filed Mar 26, 2022 01:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0001326110-22-000018 · wf-form4_164825664654486.xml · derivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-03-23 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022. Read SEC document |
| February 05, 2022 Filed Feb 9, 2022 01:53 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-22-000006 · wf-form4_164437159900979.xml · derivative · entry 4 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 83,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F4 · derivative.exercise_date: Subject to the Reporting Person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. F4 · derivative.expiration_date: Subject to the Reporting Person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. Read SEC document |
| February 05, 2022 Filed Feb 9, 2022 01:53 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 29,415 | $5.39 | $158,546.85 |
DisclosureSEC source: 0001326110-22-000006 · wf-form4_164437159900979.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,094 F2 · price: On February 5, 2022, the Reporting Person's RSUs vested. The RSUs were settled on February 7, 2022, the first business day following the vesting date. The closing price of Immunity Bio, Inc.'s common stock on February 4, 2022 was the settlement price used to calculate the shares withheld. Read SEC document |
| February 05, 2022 Filed Feb 9, 2022 01:53 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001326110-22-000006 · wf-form4_164437159900979.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| October 08, 2021 Filed Oct 9, 2021 00:31 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | PurchaseCommon Stock | 1,923 | $8.81 | $16,932.02 |
DisclosureSEC source: 0001326110-21-000005 · wf-form4_163373943704706.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,930 F1 · ownership.nature: Shares held by girlfriend living in the same household as the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 08, 2021 Filed Oct 9, 2021 00:31 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | PurchaseCommon Stock | 7 | $9.00 | $63.00 |
DisclosureSEC source: 0001326110-21-000005 · wf-form4_163373943704706.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7 F1 · ownership.nature: Shares held by girlfriend living in the same household as the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055785 · doc4.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,800 Underlying: Common Stock · 8,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F2 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Tax withholdingCommon Stock | 4,273 | $9.95 | $42,516.35 |
DisclosureSEC source: 0001209191-21-055785 · doc4.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,176 Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:32 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055785 · doc4.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Read SEC document |
| March 09, 2021 Filed Apr 15, 2021 00:18 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | OtherRestricted Stock Units · Derivative | 172,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026746 · doc4.xml · derivative · entry 1 Adcock Richard · CIK 0001830328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,420 Underlying: Common Stock · 172,420 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. F2 · kind: Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2020, by and among NantKwest. Inc. ("NantKwest"), Nectarine Merger Sub, Inc., a wholly owned subsidiary of NantKwest ("Merger Sub"), and ImmunityBio, Inc. ("ImmunityBio"), Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of NantKwest and was renamed NantCell, Inc. Following the completion of the merger, NantKwest was renamed ImmunityBio, Inc. In the merger, NantKwest issued to the stockholders of ImmunityBio 0.8190 of a share of its common stock, par value $0.0001 per share, for each outstanding share of ImmunityBio common stock, and the derivative securities of ImmunityBio were also correspondingly converted to derivatives of NantKwest at the same ratio. F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · derivative · entry 6 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the RSU award shall vest on the date of grant. F4 · derivative.expiration_date: One hundred percent (100%) of the shares subject to the RSU award shall vest on the date of grant. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · derivative · entry 5 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the RSU award shall vest on the date of grant. F4 · derivative.expiration_date: One hundred percent (100%) of the shares subject to the RSU award shall vest on the date of grant. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · derivative · entry 4 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $23.72 | $0.00 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · derivative · entry 3 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-02-05 F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 5, 2021. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Tax withholdingCommon Stock | 68,171 | $23.72 | $1,617,016.12 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · nonDerivative · entry 2 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,829 Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:47 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009135 · doc4.xml · nonDerivative · entry 1 Adcock Richard · CIK 0001830328 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.